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Abstract The importance of extracellular matrix (ECM) in-
tegrity in maintaining normal tissue function is highlighted by
numerous pathologies and situations of acute and chronic in-
jury associated with dysregulation or destruction of ECM
components. Heparan sulfate (HS) is a key component of
the ECM, where it fulfils important functions associated with
tissue homeostasis. Its degradation following tissue injury dis-
rupts this delicate equilibrium and may impair the wound
healing process. ReGeneraTing Agents (RGTA®s) are poly-
saccharides specifically designed to replace degraded HS in
injured tissues. The unique properties of RGTA® (resistance
to degradation, binding and protection of ECM structural and
signaling proteins, like HS) permit the reconstruction of the
ECM, restoring both structural and biochemical functions to
this essential substrate, and facilitating the processes of tissue
repair and regeneration. Here, we review 25 years of research
surrounding this HS mimic, supporting the mode of action,
pre-clinical studies and therapeutic efficacy of RGTA® in the
clinic, and discuss the potential of RGTA® in new branches of
regenerative medicine.
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Introduction
The processes governing tissue repair and regeneration involve
the interplay between cells and signaling molecules, within the
context of a three dimensional extracellular matrix (ECM). A
growing number of observations have demonstrated that hep-
aran sulfates (HS) are essential components of the ECM, via
their ability to store, protect and regulate the bioavailability of
communication factors required for normal one-to-one cell
replacement or tissue repair [1]. The destruction of HS follow-
ing tissue injury, liberates cytokines from this protectivematrix
compartment and destabilizes the tissue microenvironment.
RGTA®s (ReGeneraTing Agents) are chemically
engineered polymers that are specifically designed to replace
degraded HS in the injured matrix compartment. By seques-
tering proteins through low affinity binding, RGTA® protects
naturally existing structural and signaling proteins, and in do-
ing so, enhances the speed and quality of tissue repair. The
mechanism of action and effects of RGTA® have been inves-
tigated inmany systems of tissue injury, with often remarkable
results. In this review, we summarize our current understand-
ing of the mode of action of RGTA® and provide key exam-
ples of RGTA®’s efficacy in pre-clinical models and in
humans. These studies demonstrate that RGTA®-based resto-
ration of the ECM and triggering of tissue regeneration repre-
sent an effective way to treat diverse pathologies, constituting
a clinically evidenced, new branch of regenerative medicine.
The extracellular matrix and its role in tissue
homeostasis
TheECM is a network ofmacromolecules that includes a plethora
of structural proteins, enzymes and soluble factors, which interact
in a dynamic fashion with surrounding cells, in order to maintain
tissue structure and homeostasis. The ECM can be divided into
the interstitial connective tissue matrix, a structural tissue compo-
nent surrounding cells and the basement membrane, which delin-
eates the epithelium from the underlying tissue. Analysis of the
mammalian ‘matrisome’ has defined a list of approximately 300
central ECM proteins. These include collagens, the major struc-
tural components of the ECM, proteoglycans (PGs), core pro-
teinswith attached glycosaminoglycan (GAG) chains that seques-
ter water and bind growth factors, and glycoproteins, which play
diverse roles in ECM structure and communication, and also act
as a reservoir for growth factors. In addition to these central pro-
teins, the ECM also includes numerous other proteins such as
enzymes, growth factors and cytokines, which play important
roles in homeostasis and remodeling [2]. The ECM of each tissue
is a unique composition of these elements in three dimensional
space and controlling the delicate balance of enzymatic and non-
enzymatic activities is crucial for normal tissue function. This is
underscored by the existence of numerous pathologies associated
with dysregulated ECM components including osteoarthritis, fi-
brosis and cancer [3, 4].
HSs are a subclass of sulfated GAGs that play a key role in
the regulation of tissue homeostasis bymediating and integrat-
ing communication events. In the ECM, these exist as heparan
sulfate proteoglycans (HSPGs), which comprise a core protein
to which one or several HS chains are covalently linked.
HSPGs may be expressed on the surface of cells (syndecans,
glypicans), secreted in the ECM (agrin, perlecan, type XVIII
collagen) or in secretory vesicles (serglycin). In brief, HS is a
crucial element of the ECM, fulfilling both an:
1. Architectural Role: HSPGs bind matrix proteins such as
collagens, fibronectin and laminin at specific ‘heparan sul-
fate binding sites’, protecting these proteins from proteolytic
degradation and forming a scaffold around cells, thereby
contributing to the spatial organization of the ECM [1] and a
2. Protection Role: The structural complexity (degree of
substitution and position of sulfate groups) of HS is di-
verse, and allows HS to specifically bind peptides and
ECM matrix proteins [5]. By binding growth factors, cy-
tokines and chemokines, HSPGs protect factors from deg-
radation and control their retention, thereby regulating
their local concentration and signaling capabilities. In
some cases, factors remain bound to HS upon binding
their respective receptors, such that the HSPG ‘presents’
the ligand to its respective receptor, whereas in other cases
cleavage of the factor fromHS is required for function [1].
Extensive tissue damage is typically followed by normal
wound repair, a sequence of events involving hemostasis and
inflammation, proliferation and tissue remodeling. During this
process, cells involved in the inflammatory response (macro-
phages, neutrophils) and resident cells at the wound site
(keratinocytes, fibroblasts and endothelial cells) release
heparanases and proteases into the injured tissue [6]. This
leads to the degradation of HS, destruction of the ECM scaf-
fold, and the release of HS-bound communication polypep-
tides into the ECM, stimulating the rapid repair of tissue, and
is accompanied by resolution of the inflammatory response.
This repair process results in scars or fibroses, and while the
resultant tissue provides a barrier to prevent further infection,
the quality of tissue is lower, both structurally and aesthetical-
ly. In the case of chronic wounds, however, such as those
associated with diabetes mellitus and vasculitis, the wound
remains in a state of chronic inflammation. The increased
proteolytic activity, caused by persisting inflammatory cells,
leads to degradation of ECM, structural proteins and growth
factors required for repair, and the ECM microenvironment is
trapped in a cycle of repair and destruction [6].
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RGTA®matrix technology –Heparan sulfate mimics
in tissue regeneration
Matrix therapy is based on the concept of restoring the cellular
microenvironment, which is disrupted following tissue injury,
with the aim of promoting communication between cells and
re-establishing tissue homeostasis. ReGeneraTing Agents are
heparan sulfate mimics, specifically designed to replace de-
graded heparan sulfates in damaged tissue, accelerating the
speed and enhancing the quality of tissue repair. Their unique
properties have been subject of intensive pre-clinical studies
and we are now at the point where the clinical utility of these
polymers is being fully realized.
RGTA® – Chemical structures and stability
RGTA®s are chemically substituted polymers with sulfates and
carboxyl groups, to which other groups such as fatty acids,
amino acids or other substances of pharmacological interest
may be added in specific amounts and locations, based on their
performance in vitro (interaction with matrix proteins and
growth factors) and in vivo (tissue regeneration capabilities).
Importantly, this hemisynthetic pathway is highly controlled,
allowing the design and production of well characterized mol-
ecules with significant therapeutic value [7]. While several oth-
er substituted polysaccharides or copolylactic and malic copol-
ymer backbones also fulfil the RGTA® definition [8], dextran
has been preferred for reasons of safety and accessibility.
Although structurally and functionally analogous to natural-
ly derived HS, one of the most crucial properties of RGTA® is
its resistance to enzymatic degradation. This allows RGTA®s to
retain their structure and activity even in the microenvironment
of chronic wounds, characterized by unrestrained proteolytic
activity [6, 9]. In injured tissue, HS, present at the cell surface
and within the ECM, is degraded by heparanase, and other
ECM components, required for wound healing and homeosta-
sis, are destroyed by locally secreted proteases. Unlike HS di-
saccharide subunits, which are linked by β1-4 carbon-carbon
bonds sensitive to enzymatic cleavage, RGTA® subunits are
linked by α1-6 carbon-carbon bonds, rendering RGTA®
completely resistant to degradation by endoglycosidases known
to digest natural GAGs, including chondroitinase ABC, dex-
tranase, hyaluronidase and a mixture of heparitinases I, II and
III [9]. In this way, RGTA® can replace destroyedHS, reversing
the hostile microenvironment and fostering tissue healing.
RGTA® mode of action - Structural and protective roles
The degradation of HS at the site of injured tissue, leads to the
disorganization of the ECM and exposes structural and
communication-proteins to protease activity. RGTA® fosters res-
toration of the natural architecture of the ECM by specifically
localizing to the injured tissue [10], where it may bind free
‘heparan binding sites’ present in structural proteins such as col-
lagen, fibronectin and laminin [11]. This binding has two impor-
tant consequences. Firstly, it serves to protect the matrix proteins
from proteolytic degradation and secondly, it facilitates recon-
struction of the ECM scaffold, a necessary first step in
reestablishing a microenvironment conducive to tissue repair
(Fig. 1).
The ability of RGTA® to protect and thereby potentiate sig-
naling peptides and growth factors, re-establishing theECMcom-
munication network, is another key feature underlying the thera-
peutic action of RGTA® and is well documented. In chronic
wounds, the levels of growth factors required for matrix forma-
tion, remodeling, formulation of granulation tissue and re-
epithelialization are decreased. This is due, in part, to the high
levels of proteolytic enzymes released by inflammatory cells as
well as the presence of reactive oxygen species. RGTA® binds
numerous heparin-binding growth factors including FGF [12],
VEGF [13] and TGFβ [14], or chemokines such as SDF-1 [15]
and in doing so, controls their bioavailability, protects them from
proteolytic degradation [16–18] (which may be due to the pro-
tective effect of direct binding and/or due to the ability of RGTA®
to inihibit enzymes such as plasmin or neutrophil elastase) and
may also increase affinity for their receptors [12, 13]. By
reestablishing the spatio-temporal distribution of growth factors,
RGTA®may influence important processes contributing to tissue
healing and regeneration such as cell migration and differentiation
[19, 20] and angiogenesis [13], in addition to providing general
protection against oxidative stress [21] and apoptosis [22].
Our current understanding of RGTA®’s mode of action
points to a relatively simple mechanistic model, whereby
RGTA® readily replaces degraded GAGs and particularly HS,
in an altered ECM. In this way, RGTA® selectively protects
heparin binding cytokines and structural proteins, facilitating
natural matrix reorganization and favoring tissue homeostasis
and/or repair. Although no specific receptors for RGTA®s are
known, one can consider that because of its capacity to interact
with a diversity of HS binding proteins in the ECM, RGTA® is
a HBP low affinity receptor mimic. Moreover, since RGTA® is
biodegraded when internalized and catabolized through lyso-
somal pathways within cells (Barritault, unpublished data), as
for other matrix elements, other possible roles for RGTA® at the
intracellular level can be discounted. However, to strongly sup-
port this hypothesis, further studies are required and this is the
focus of ongoing research. The turnover of the matrix constitu-
ents is tissue specific, and is also dependent on the degree of the
injury. The extent of RGTA® induced restoration will depend
on the dose and frequency of application. Once reorganization
of the matrix is achieved, and matrix protein binding sites are
saturated, additional RGTA® may in fact be deleterious, with
excess, unbound RGTA® attracting already bound factors away
from the site of injury (Fig. 1). Hence dosing and timing need to
be adaped to reflect the matrix turnover, which varies from
tissue to tissue and according to the stage of healing. By
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restoring the extra-cellular microenvironment, RGTA® favors
the formation of a niche for resident or therapeutic cell homing,
in accordance with the nascent concept of matrix/cell therapy.
This concept is currently paving the way towards RGTA®-
based matrix and (stem) cell therapy combinations [23, 24].
RGTA® Pre-clinical models
The therapeutic potential of RGTA® has been the subject of
intense research, and over the past 25 years, the efficacy of
these heparan sulfate analogs in improving wound healing in
numerous pathological contexts and tissues has been demon-
strated (Table 1).
Skin
The ability of RGTA® to accelerate and improve the quality of
skin wound healing is well documented in pre-clinical models,
and the results of these studies have been instrumental for the
transition of RGTA® from the bench into the clinic. Indeed,
RGTA® has been successfully used to treat diabetic foot ulcers
and chronic ulcers from other origins including prolonged
pressure on the skin, misfunctioning of venous valves, due
to sickle cell disease, following extensive burns and in cancer
patients post-irradiation (see below).
In the context of treating diabetic ulcers, pre-clinical animal
models, recapitulating lesions observed in human patients, are
particularly relevant, since impaired wound healing may be
attributed to several factors underlying the pathophysiology of
this disease. For example, the production of advanced
glycation end products that induce production of inflammato-
ry molecules and affect collagen synthesis [50], and ischemia
resulting from macro or microvascular disease [51]. In a mod-
el of ischemic wounds in diabetic rats, weekly intramuscular
injection of RGTA® enhanced the speed and total closure of
wounds and improved the mechanical strength of scar tissue.
This was associated with reduced inflammation, enhanced
angiogenesis and increased collagen content (increased colla-
gen I and decreased collagen III biosynthesis) [25]. Similarly,
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Fig. 1 Mode of Action of ReGeneraTing Agent (RGTA®) Following
Extensive Tissue Damage. 1. The Extracellular Matrix (ECM) organiza-
tion in healthy tissue (left panel). Blue dots correspond to communication
peptides, stored and protected by glycosaminoglycans. Heparan sulfate
(HS) (light pink helices) links the matrix proteins (white fibers) to form a
scaffold around cells. 2. Following extensive tissue damage, HS is de-
graded by glycanase (yellow figurines), the ECM scaffold structure is
destroyed and proteases (yellow figurines) may enter, destroying matrix
proteins and stored growth factors. 3. A rapid repair response is triggered
resulting in scars or fibroses. 4. If the cause of the lesion is not resolved,
wounds remain in an inflammatory phase, leading to a cycle of repair and
destruction. 5. RGTA® (green helices) replaces degraded HS, allowing
reconstruction of the ECM scaffold and restoring the cellular microenvi-
ronment. This facilitates tissue regeneration and restoration of tissue to a
state similar to that of healthy tissue. 6. Excess RGTA® may hinder the
healing process by drawing growth factors and communication peptides
away from the wound site. In this situation, the bioavailability of growth
factors required for efficient wound healing is reduced, emphasizing the
need to optimize the RGTA® treatment protocol (dose and timing) in
accordance with the tissue specific matrix turnover
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Table 1 The effects of RGTA® treatment in pre-clinical models
Model Effects of RGTA® Treatment References
Skin
Ischemic wounds in a diabetic context -Acceleration of wound healing, total closure. Tong et al. [25]
Necrotic ulcers -Acceleration of ulcer closure.
-Normalization of collagen III/I levels.
-Reduced inflammation.
Barbier-Chassefiere et al.
[26]
Full-thickness excisional wounds -Increased local vascular response.
-Increased skin strength.
Tong et al. [19]
Deep second degree burns -Accelerated epidermal repair.
-Decreased zone of stasis and extent of dermal remodeling.
Zakine et al. [27]
Burn-related skin fibrosis -Normalization of collagen III/I levels.
-Increased activity of MMP-2 and MMP-9.
Garcia-Filipe [28]
Cornea
Corneal alkali burn -Enhanced re-epithelialization.
-Reduction in ocular inflammation.
-Histological changes (reduced edema, fibrosis, blood vessels,
inflammatory cells).
Brignole-Baudouin et al.
[29]
Corneal alkali burn -Decreased corneal inflammation.
-Enhanced re-epithelialization.
-Decreased neovascularization.
-Healing of corneal ulcers following application 1 month post-injury.
Cejkova et al. [30]
Post-surgical corneal ulcers -Increased corneal transparency.
-Increased corneal thickness and epithelial cell organization.
-Decreased myofibroblasts.
-Increased nerve terminal density.
Riestra [31]
Oral and Digestive Tract
5-fluorouracil induced mucositis -Prevention of mucositis and reduction of area and thickness of lesions.
-Protection of basement membrane.
Morvan et al. [32]
Irradiation induced oral mucositis -Protection of lip mucosa from irradiation induced damage.
-Improved tissue structure and mucosal thickness.
-Reduced collagen deposition.
-Decreased infiltration of leukocytes.
Mangoni et al. [21]
Periodontitis -Reduced gingival tissue inflammation.
-Restored alveolar bone.
Escartin et al. [33]
Periodontitis -Restoration of gingival ECM.
-Restoration of basement membrane.
-Restoration of alveolar bone and interradicular bone.
Lallam-Laroye et al. [34]
Periodontitis -Restoration of alveolar bone.
-Restoration of periodontal attachment.
Lallam-Laroye et al. [35]
Ethanol-induced gastric lesion and
acetic acid induced colitis
-Decreased severity of lesions. Meddahi et al. [36]
Colonic anastomosis -Increased resistance of anastomosis to leakage. Meddahi et al. [37]
Bone, Joint and Tendon
Craniotomy defects -Increased bone filling rate.
-Increased number of small vascular channels in newly formed bone.
-Increased collagen I, III and fibronectin.
-Increased osteoprogenitors.
Lafont et al. [38]
Partial thickness calvarial defects -Accelerated bone healing.
-Evidence of osteoblastic activity and bone remodeling.
-No foreign body reaction observed, in contrast to controls.
Albo et al. [39]
Long bone defects -Formation of new bone exhibiting continuity of the diaphysis,
corticalization and a medullar canal.
Blanquaert [40]
Superficial digital flexor tendonitis
(field study)
-Higher earnings post-injury compared to matched controls.
-Earlier return to racing compared to matched controls.
Coudry et al. [41]
Superficial digital flexor tendonitis
(controlled clinical trial)
-Decreased cross sectional area over time.
-Higher number of races and victories.
-Lower rate of reinjury.
Jacquet-Guibon,
unpublished
Muscle
Myocardial infarction (pig) -Reduced loss of myocardial function.
-Reduced infarct size.
-Fecreased fibrotic tissue.
Yamauchi et al. [42]
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in a rat necrotic skin ulcer model, which more closely mirrors
chronic wounds in humans compared to healthy skin repair
models, topical administration of RGTA® significantly accel-
erated ulcer healing and this was accompanied by decreased
recruitment of leukocytes and normalization of collagen III/I
ratios and improved dermal reconstruction [26]. Increased
skin strength and vascular response following RGTA® treat-
ment were also observed in a rat excisional woundmodel [19].
Hypertrophic scar formation following burns and trauma re-
mains a serious clinical problem and may be associated with a
loss of function as well as disfigurement, significantly affecting
patient quality of life. That RGTA® improves wound healing
quality and reduces the extent of fibrosis therefore has advan-
tages not only from a functional point of view, but also from an
aesthetic perspective. This extends the use of RGTA® into re-
constructive surgical procedures (see below) and in the case of
burns. In a rat model of deep second degree burns, RGTA®
accelerated epidermal repair between days 3–7 post-treatment,
as evidenced by the increased number of keratinocyte layers and
staining for cytokeratin 14 [27]. Additionally, the size of the
zone of stasis, which corresponds to delayed vascular lesions
between the burn injury and adjacent healthy tissue, was smaller
in RGTA® treated animals. In a similar burn model, RGTA®
was capable of normalizing the ratio of collagen III/collagen I,
which is often skewed towards high levels of collagen III in
injured or in fibrotic tissue, and also increased the activity of
MMP-2 and MMP-9, key regulators of ECM remodeling [28].
Cornea
Significant potential exists for RGTA® in the treatment of ocu-
lar surface diseases, with key studies showing that RGTA®
controls ocular surface inflammation and enhances corneal
healing. In a rabbit corneal alkali burn model, a single treatment
with RGTA®, at the time of injury, improved corneal healing, as
assessed by reduced inflammation, enhanced re-
epithelialization and specific histological patterns (decreased
edema, fibrosis, blood vessels and inflammatory cells), with
tissue organization closely mirroring that of normal cornea
[29]. Later studies using a similar corneal alkali burn model,
showed that RGTA®, applied 1 h following injury, accelerated
corneal healing, associated with a decrease in corneal thickness
and suppressed inflammation and neovascularization compared
to controls. Importantly, RGTA® also healed ulcers when ap-
plied 1 month after injury, indicating that RGTA® not only
exerts a post-injury protective effect, but also acts to actively
promote healing of injured tissues [30]. Following corneal in-
jury, levels of antioxidants are decreased in the cornea, creating
an imbalance between prooxidants and antioxidants, and the
resulting toxic oxygen and nitrogen products also contribute
to corneal damage. In this model, RGTA® reduced the expres-
sion of enzymes generating superoxide radicals and nitric oxide
as well as proteolytic enzymes, thereby fulfilling a dual role:
protecting the cornea from damage induced by excessive pro-
teolysis as well as toxic oxygen and nitrogen products [30].
Table 1 (continued)
Model Effects of RGTA® Treatment References
-Preservation of myocytes.
-Increased number of blood vessels.
Myocardial infarction (baboon) -Trend towards increased myocardial function. Mullangi et al. [23]
Ischemic and denervated EDL muscle -Inhibition of epimysial post-inflammatory reaction.
-Increased peripheral zone and surviving muscle fibers.
-Enhanced regeneration of muscle fibers and revascularization.
Desgranges et al. [43]
Ischemic EDL muscle -Inhibition of ischemic process.
-Acceleration of muscle fiber maturation.
-Stimulation of muscle fiber regeneration.
-Increased microvessel density.
Chevalier et al. [44]
EDL muscle crush -Increased number of muscle fibers. Gautron et al. [45]
EDL and soleus muscle crush and nerve
cut
-Increased axonal growth and synaptic differentiation. Aamiri et al. [46]
Other Models
Sciatic nerve crush -Decreased adherence of nerves to surrounding tissue. Zuijdendorp et al. [47]
Implantation of foreign materials -Improved foreign body reaction to implanted polyethylene
terephthalate (PET).
-RGTA® coating of PET decreased the number of inflammatory giant
cells.
-Injected RGTA® increased vascularization in tissue surrounding the
implant and prevents deposition of collagen.
van Bilsen et al. [48]
Tympanic perforation repair -Reduced thickness of the tympanic membrane.
-Improved cellular reorganization.
Hellstrom, unpublished
Tauopathies -Blocked neuronal uptake of tau fibrils. Holmes et al. [49]
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Furthermore, in a mouse model of corneal ulcers following
photorefractive keratectomy (PRK), RGTA® treatment in-
creased the degree of corneal transparency and improved cor-
neal epithelial cytoarchitecture and nerve regeneration, and de-
creased or delayed the presence of stromal myofibroblasts [52].
Oral and digestive tract
Pre-clinical data demonstrating the efficacy of RGTA® in oral
and gastrointestinal tract associated lesions have also shown
promise in the treatment of acute or chronic ulcers, during
cancer treatment or following surgical procedures such as sur-
gical anastomosis.
Oral mucositis, a complication of cancer treatment, particu-
larly chemotherapy and radiation, causes atrophy of the mucosal
lining of the mouth and the formation of ulcers, increasing the
risk of infection and severely affecting patient quality of life. In a
model of oral mucositis induced in hamsters by 5-fluorouracil
(5-FU), RGTA® prevented mucositis in 50 % of treated animals
and significantly reduced the mean lesion volume in the remain-
ing animals [32], effects that may be explained, at least in part,
by the ability of RGTA® to inhibit plasmin activity to normalize
the balance of MMP-TIMPs, and to protect factors required for
tissue healing such as TGFβ. The beneficial effects of RGTA®
in this model were also associated with protection of the base-
ment membrane, evidenced by preservation of laminin and type
IV collagen, consistent with the known protective role of
RGTA® on heparan binding matrix proteins. Importantly, treat-
ment with RGTA® did not interfere with the effects of 5-FU
treatment on epithelial cell growth and no effects on body
weight or blood cell counts were observed.
In a mouse irradiationmodel, RGTA® also showed a strong
anti-oxidative and protective effect resulting in reduced in-
flammation, less tissue destruction and improved recovery,
highlighting its potential as a skin protector following radio-
therapy [21].
RGTA® also had marked effects in a hamster model of
periodontitis, a common disease affecting the supporting tissue
of the tooth, that can result in tooth loss or other associated
health problems. Periodontitis is triggered by bacteria, and is
characterized by inflammation and destruction of the gingival
tissue and bone supporting the tooth. In this model, following
the induction of disease, weekly intramuscular injections of
RGTA® reduced gingival tissue inflammation and bone loss,
leading to the eventual restoration of alveolar bone and the
regeneration of a functional periodontal ligament [33–35].
These effects were associated with an increase in the number
of ERM (epithelial rests of Malassez) cells, which play roles in
centenum repair and regeneration, and increased expression of
bone morphogenic proteins (BMPs). Thus, RGTA®, via its
ability to reestablish the cellular microenvironment and protect
growth factor activity, is implicated in the survival, recruitment
and proliferation of cells essential for regeneration.
In both ethanol-induced gastric lesion and acetic acid-
induced colitis models, treatment with RGTA® led to a marked
reduction in the severity of lesions. In these models RGTA®
was administered before and shortly after induction of injury,
and the protective effect of RGTA® may be explained by its
anti-inflammatory action and ability to protect the ECM and
HBGFs required for tissue repair and angiogenesis [36].
Lastly, in a wound healing model of colonic anastomosis,
RGTA® increased the resistance of the anastomosis to leakage
at early time points, highlighting its potential application as a
post-surgical sealing agent [37]. This increased mechanical
strength may at least in part be attributed to the ability of
RGTA® to inhibit the degradation and/or promote the synthe-
sis of intestinal wall structural components such as collagen,
possibly by increasing the bioavailability of TGFβ.
Bone, joint and tendon
As mentioned above, RGTA® reduced bone loss in a hamster
model of chronic periodontis, leading to the eventual restoration
of alveolar bone and the regeneration of a functional periodontal
ligament [33–35]. Some of the most remarkable effects of
RGTA® on tissue regeneration were also observed in bone using
models of surgical defects and inflammatory bone destruction. In
a rat model of craniotomy defects, where spontaneous healing
does not occur, RGTA® led to near complete bone filling, com-
pared to controls where bonewas only formed at the edges of the
defect, and this was associated with an increase in
osteoprogenitors and in type I and III collagen and fibronectin,
suggesting that RGTA® reactivated events paralleling those oc-
curring during development [38, 53]. The new bone exhibited a
higher number of small vascular channels where bone remodel-
ing was observed [38]. Moreover, when the trephine hole was
performed on both sides of the parietal bone including part of the
sagittal suture, a newly formed suture was seen in the new bone
in continuation with the remaining suture from the borders
(Fig. 2). In support of these observations, RGTA® also acceler-
ated healing of bone-wounds in a model of partial thickness
calvarial defect in rabbits [39]. In a rat long bone defect model,
where a third of the total length of an adult femur was replaced
by a pinned, demineralized, autologous bone soaked overnight in
either saline or RGTA®, the RGTA®-impregnated bone prosthe-
sis formed a new bone exhibiting corticalization and a medullar
canal in 2 months. In contrast, non-organized bone cell coloni-
zation and formation of a callus was observed in control rats [24].
The effect of RGTA® on tendon regeneration is best illus-
trated in the tendon to tendon slow and fast muscle crush
models [45, 46] (see below). The efficacy of RGTA® has also
been demonstrated in the treatment of race horses with tendon
rupture. In a field study involving 51 horses, comparison of a
subset of RGTA®-treated horses with a matched control
group, revealed that RGTA®-treated horses returned to racing
earlier and performed better than non-treated horses [41].
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These results were confirmed in a randomized, controlled trial
of racing French Standardbred trotters presenting with super-
ficial digital flexor tendonitis. Horses treated with a single,
intra-lesion injection of RGTA® exhibited improved healing,
presented with a higher number of races and victories and
benefited from a decreased reinjury rate compared to controls
(Jacquet-Guibon, unpublished data). In the case of ligaments,
the only reported effect of RGTA® to date, is in the restoration
of a functional periodontal ligament as mentioned above [35].
Muscle
The potential of RGTA® in the treatment of muscle injuries,
including those induced by ischemia, is supported by several
studies showing that RGTA® can enhance muscle regenera-
tion, reinnervation and revascularization.
In a model of acute myocardial infarction induced by liga-
tion of the left circumflex artery in pigs, RGTA® exerted a
protective effect, evidenced by a 50 % reduction in the size of
the infarct and higher recovery of the left ventricular ejection
fraction compared to control treated animals. RGTA®-treated
animals also exhibited reduced fibrotic tissue formation, in-
creased numbers of blood vessels and preservation of
myocytes, highlighting the potential for RGTA® in the treat-
ment of ischemic heart disease [42]. In support of these re-
sults, RGTA® also improved the recovery of myocardial func-
tion following acute myocardial infarct (MI) in a Baboon
model, with a reduced ejection fraction of 24.7 % observed
in controls after 2 months compared to only 12 % in RGTA®-
treated baboons [54].
Similarly, in a model of ischemic EDL (extensor digitorum
longus) muscle in rats, a single injection of RGTA® adminis-
tered at the time of injury had marked effects at three levels.
Firstly, the thickness of the epimysium of RGTA® treated
muscle was normal, comprising thin connective tissue, in
comparison to the thick layer observed in controls.
Secondly, RGTA®-treated muscle contained a larger peripher-
al zone containing a higher number of surviving muscle fibers
and this area was interspersed with less connective tissue com-
pared to controls and thirdly, the architecture and distribution
of new fibers in the regenerating zone was increased in
RGTA®-treated muscle, compared to controls, which exhibit-
ed few regenerated myotubes and necrotic muscle fibers.
Additionally, vascularization was enhanced in RGTA®-
treated muscle. Thus RGTA® has a radial effect in muscle,
providing both protection and regeneration of muscle fibers
following injury [43, 44].
In a rat model of skeletal muscle damage induced by ten-
don to tendon crush, injured fast (EDL) and slow (soleus;
SOL) muscle treated with a single injection of RGTA®, ex-
hibited increased muscle fiber density and maturation, re-
duced fibrosis and more mature motor endplates and multi-
axon connections [24, 45, 46]. Crushed tendon and overall
muscle functional recovery were assessed by electromyogra-
phy, and demonstrated that tendon to tendon crushed EDL
muscles recovered total function (compared to non-injured
contralateral muscle) versus 60 % in saline treated muscle.
Fig. 2 Filling of craniotomy defects. A. Operative view of the defect. X-
ray of defects treated with a collagen plaster soaked in 30 ul of B. saline,
C. RGTA® solution (25 μg/ml) D. RGTA® solution (100 μg/ml) and E.
RGTA® solution (400 ug/ml), after 4 weeks. F. Full macroscopic view of
the skull defect with top arrows showing both sides of the defect and
bottom arrows indicating new bone formation. Note the convex shape
of the new bone structure, matching with expected original bone. v at the
center indicates the saggital vein. G. Enlargement showing the lamellar
organization of the flat bone as expected from a skull. H. alkaline phos-
phatase positive osteoblastic cells
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Similarly, SOL muscle recovered 85 % ± 15 % compared to
no recovery in saline injected muscles [24].
Other models
The efficacy of RGTA®-based matrix therapy has also been
documented in several other models, including a rat model of
sciatic nerve crush, where RGTA® significantly reduced the
force needed to break adhesions between the nerve and sur-
rounding tissue [47], hence demonstrating anti-adhesion and
anti-fibrosis properties.
The utility of RGTA® as a substance to improve the foreign
body reaction to implanted biomaterials such as poly(ethylene
terephthalate)(PET) by increasing vascularization in the tissue
surrounding the implant and reducing inflammation has also
been demonstrated, highlighting its potential as a beneficial
agent following implantation of medical devices [48].
In a rat model of tympanic membrane perforation, RGTA®
led to enhanced healing, reducing the thickness of the tym-
panic membrane to that of intact controls and improving cel-
lular reorganization (Hellstrom et al., unpublished data). The
potential of RGTA® in the treatment of Alzheimer’s disease
and other tauopathies has also been demonstrated, with a re-
cent study showing that RGTA® blocks neuronal uptake of tau
fibrils in vivo [49].
Modes of administration
RGTA® can be administered both locally and systemically, and
in certain preclinical models, one local application of RGTA®
was sufficient to regenerate injured tissues. In the rat EDL mus-
cle crushmodel described above, systemically deliveredRGTA®
was rapidly eliminated from the system, with specific uptake
observed at the site of the injured tissue, supporting the model
whereby RGTA® binds heparan binding sites made available
following destruction ofHS in damaged tissue [10]. In this study,
RGTA® was detected in injured EDL muscle at least 1 week
after injection, highlighting its stability and providing a rationale
for its efficacy after a unique application. The pharmacokinetics
and biodistribution of RGTA® in other models of tissue damage
are now being investigated and will be important for optimizing
the dose and timing schedule of RGTA®.
RGTA® in the clinic
RGTA® is already used in clinics in two commercially available
products (OTR4120, alpha1-6 polycarboxylmethylsulfate glu-
cose), one for the treatment of chronic skin lesions1 and the
other for the treatment of corneal lesions.2 A second derivative,
OTR4131 (alpha1-6 polycarboxylmethylsulfateacetate glu-
cose), has shown efficacy in tendon and muscle regeneration
and is now at the marketing registration stage.
Skin wounds
RGTA® matrix therapy has been successfully used to treat pa-
tients with a wide spectrum of wound types, since the mode of
action is independent of the origin or cause of the lesion. Most
cases concern chronic ulcers, associated with severe limb ische-
mia [55] (Roohi, in preparation), diabetes [56–58], burns [57,
59] pressure [57] and vascular defects [57], as well as in individ-
ual patients presenting with ulcers caused by sickle cell disease
[60] radiation [61] and epidermolysis bullosa [62] (Table 2). In
addition to chronic wounds, RGTA® has also been used to treat
patients with acute wounds [63] and following plastic skin sur-
gery for scar reduction and orbital adhesion in centrofacial lifting
[64]. To date, over 20 000 patients have already benefited from
RGTA® treatment, with no adverse effects yet reported.
In a cohort of 12 patients presenting with non-healing ulcers
due to severe limb ischemia (14 ulcers total), RGTA® led to a
significant decrease in the mean ulcer surface area compared to
baseline at 4 weeks, and this was associated with increased
granulation tissue [55]. After 3 months, 50 % of ulcers had
completely healed and in a long term follow up of 9 patients,
no reopening of closed ulcers was observed and no amputations
were performed as a result of ulcers [55]. Similarly, in a study of
diabetic patients presenting with non-healing foot ulcers, treat-
ment with RGTA® led to complete wound closure in 6 out of 10
patients, and a significant reduction in wound area in the re-
maining patients, after 10 weeks [56]. In a recent study involv-
ing type 2 diabetic patients with therapy resistant foot and lower
extremity ulcers, local application of RGTA® twice weekly led
to complete healing in all patients (12/12) [58].
The remarkable response of patients to RGTA® therapy in
these clinical studies, particularly in light of the fact that many
of these patients had failed to respond to standard treatment
for a prolonged time, and were in therapeutic failure, despite
provision of high-end care, underscores the potential for
RGTA® as a simple, first-line treatment in the management
of chronic ulcers. Furthermore, in several studies, marked pain
relief was observed by patients [57], and while the mechanism
underlying this phenomenon remains unclear, this unique
property may also contribute to the enhanced quality of life
experienced by patients treated with RGTA®.
Accessibility to ECMproteins is essential for RGTA® action,
and indeed, maximum therapeutic efficacy was observed in
cases where RGTA® was applied following efficient removal
of dead tissue from the wound. Given the inconvieniences asso-
ciated with this procedure however (time consuming, painful,
requiring significant expertise), future studies will be focused on
novel treatment strategies aimed at bypassing the protective bar-
rier and optimizing RGTA® delivery to the wound site.
1 CACIPLIQ, see www.otr3.com list of trials, clinical and cases publication
2 CACICOL, see www.otr3.com list of trials, clinical and cases publication
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Corneal ulcers
To date, RGTA® has also been used to treat over 5000 patients
with injuries and defects affecting the corneal epithelium and
stroma, and its efficacy in the healing of this delicate tissue is
supported by over 100 publications documenting clinical cases
and studies (Table 2) [70–73]. Importantly, in these reports and
in ongoing studies, RGTA® was well tolerated, and no adverse
side effects have been reported. In line with our observations in
patients with chronic wounds, patients treated for corneal inju-
ries also experienced decreased pain [69], which may reflect
the anti-inflammatory properties of RGTA®.
Table 2 The effects of RGTA® treatment in clinical cases or studies
Condition or Procedure Effects of RGTA® Treatment References
Skin
Non-healing ulcers due to severe limb
ischemia
-Increased healing, increased granulation tissue.
−50 % ulcers healed after 3 months.
Desgranges et al. [55]
Ischemia post-trauma -Cases reports: rapid healing in finger and leg injuries. Roohi (unpublished data);
Desgranges et al. [55]
Sickle cell ulcer -Case report: complete healing in a patient with a wound resistant to closure. Hayek et al. [60]
Ulcers associated with Stewart-Bluefarb
syndrome
-Case report: complete healing in a patient. Hayek et al. [63]
Diabetic foot ulcers -Complete wound closure in 60 % of patients and reduction in wound area
in remaining patients.
Slim et al. [56]
Diabetic, pressure, vascular ulcers and
burns
-Complete healing of 22 % of wounds at the end of the intervention period
(up to 20 treatments sessions).
-Reduction in wound size in remaining patients after 8 weeks.
-Decreased pain.
Groah et al. [57]
Diabetic foot ulcers -Complete healing of patients (12/12) exhibiting chronic resistance to
previous therapy within 4–6 months.
Papanas et al. [58]
Heat burn -Complete healing after 4 months. Barritault et al. [59]
Abrasive and electric burns -Case reports: healing and growth of granulation tissue. Roohi (unpublished data)
Lower extremity ulcers associated with
epidermolysis bullosa
-Case report: healing of chronic, non-healing ulcers within 4 weeks. Malaq and Denis [62]
Traumatic and plastic surgery -Case report: healing and growth of granulation tissue. Roohi (unpublished data)
Plastic surgery: mammary reduction -Reduced inflammation, itching and scarring post-surgery. Zakine and Le Louarn
[64]
Plastic surgery: centrofacial lift -Reduced inflammation, swelling and bruising. Zakine and Le Louarn
[64]
Scalp lesions following surgery -Complete closure of the wound after 12 weeks. van Neck et al. [61]
Cornea
Corneal neurotrophic ulcers -Complete corneal healing in 72 % of patients after 8.7 weeks.
-Decreased average ulcer area.
Aifa et al. [65]
Corneal neurotrophic ulcer -Case report: corneal healing in a patient resistant to previous treatments. Pison et al. [66]
Corneal healing post corneal collagen
crosslinking
-Enhanced re-epithelialization compared to control treated eyes. Kymionis et al. [67]
Herpes zoster corneal neurotrophic ulcer -Case report: complete corneal healing after 2 weeks. De Monchy et al. [68]
Persistant epithelial ulcers −11 eyes treated, pain relief and improvement in 9 cases. Chebbi et al. [69]
Limbal graft failure -Successful limbal allografts after previous failures. Maringe et al. [70]
Corneal perforation associated
with Sjogren’s disease
-Corneal healing in all five treated patients. Renault et al. [71]
Epithelial basement membrane dystrophy -Corneal healing in five of six treated patients. Labetoulle et al. [72]
Dry eye associated with corneal superficial
punctate keratitis
-Reduced pain and ulcer size.
-Improved visual acuity.
Gioganti-Aurégan
(unpublished data)
Keratoconus -Complete healing observed in 80 % of eyes (40 patients)
compared to 15 % in the control group (p < 0.001).
-Decreased ocular pain.
Gumus [73]
Corneal ulcer in a child with aniridia -Corneal healing observed within 15 days. Chiambaretta
(unpublished data)
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Neurotrophic keratitis is a disease affecting the corneal ep-
ithelium that may have several underlying causes, including
herpes keratitis, chemical or physical burns, topical drug tox-
icity, irradiation diabetes, specific ocular surgical procedures,
among others. This degenerative disease is characterized by
poor corneal healing which may progress to ulcers, infection
and perforation as a result of chronic inflammation and cellu-
lar degradation or complete de novo vascularization. In a study
of patients with severe corneal neurotrophic ulcers, treatment
with RGTA® (every 2 days) led to complete corneal healing in
8 out of 11 patients after approximately 9 weeks [65],
supporting previous observations in individual patients pre-
senting with neurotropic ulcers [66, 68]. In a second study
involving 10 patients with severe corneal dystrophy or corneal
ulcers, weekly treatment with RGTA® over the course of
1 month led to improved healing and inflammation of most
ulcers, and this was associated with reduced pain [69]. In this
study, optimisation of the dose and number of treatments is
needed however, since these effects were reversed in several
patients following termination of treatment. It should be noted
that in both studies, patients were resistant to previous
treatments.
The benefit of RGTA® as a healing agent following corneal
surgery has also been demonstrated. In patients with
keratoconus, whereby the corneal epithelium was removed
using transepithelial phototherapeutic keratectomy, treatment
with RGTA® led to complete reepithelialization in 61.1 % of
eyes after 3 days, compared to 11.1 % of control eyes [67].
Taken together these studies demonstrate that RGTA® ma-
trix based therapy is an efficacious and non-invasive approach
to treat various injuries affecting the cornea and calls for future
randomized studies with larger patient cohorts. The successful
use of RGTA® with other treatment approaches has also been
demonstrated, for example bandage contact lenses which have
been shown to be effective in reepithelialization, [74], or fol-
lowing treatment with crosslinking agents in keratoconus
[73], highlighting its potential in combination treatment
strategies.
Discussion and future perspectives
Restoration of the microenvironment to facilitate natural tissue
repair is an effective solution to treat diverse pathologies, as
evidenced by the success of RGTA®-based matrix therapy in
many pre-clinical models of tissue injury and in patients, with
numerous other applications in the pre-clinical pipeline.
RGTA®, with its simple and conservative mode of action, its
glucose-based structure with only naturally existing substitu-
tions (sulfates, carboxyl and acetate groups), its ability to spe-
cifically localize to sites of injury where it is retained through-
out the restoration process [10], and its natural elimination as a
matrix element with no evidence of toxicity [75], makes it a
safe-profile product. Furthermore, RGTA® is well tolerated in
both pre-clinical models and in patients, with documented
efficacy at very low doses. Several effects of RGTA® obtained
from animal models, including the quality of tissue restoration
associated with (i) a reduction in fibrosis (ii) improvement of
collagen I/III ratios (iii) microrevascularization in ischemic
tissue, (iv) improved histological parameters and functional
recovery associated with (i) increased skin breaking strength,
(ii) reduced tissue adherence, (iii) improved recovery of heart,
muscle and locomotion functions and (iv) corneal transparen-
cy, have also been observed humans following treatment with
the first commercially available skin and corneal products.
These benefits are also expected in upcoming clinical devel-
opments and provide the basis to test RGTA® in other pathol-
ogies characterized by ECM destruction and inflammation. A
remarkable and unexpected observation documented in sever-
al trials involving both corneal and skin injuries, was the pain
relief experienced by patients shortly after RGTA® treatment.
This unexpected effect was not addressed in our initial animal
studies, however understanding the mechanisms underlying
this effect are of significant interest, since this is also an im-
portant factor affecting patient quality of life. Harnessing the
full potential of RGTA® in the clinic will require optimization
of RGTA® dosage (amount and frequency) and the mode of
administration, in a tissue dependent manner and a thorough
investigation of its efficacy in combination with other treat-
ments, such as growth factors, cells and biomaterials.
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